initial public offerings (IPOs) trading on American exchanges

Monday, October 2, 2017

Endocyte (ECYT) : exclusive worldwide license of prostate cancer drug


  • the following day:

Endocyte completes exclusive worldwide license of PSMA-617 from ABX GmbH
  • Transaction Provides Endocyte with the 'Most Advanced' Targeted Radioligand Therapy in Development for Prostate Cancer, Addressing a Greater than $1 Billion Market Opportunity
  • High Response Rates were Demonstrated in Late Stage Prostate Cancer Patients in Clinical Data Presented at Recent European Society for Medical Oncology
  • Endocyte will Focus Resources on Phase 3 Registration Trial Planned to Initiate in First Half 2018
  • Investigator Initiated Trials Intend to Support Registration and Provide Ongoing Data Assessments

No comments:

Post a Comment